Stopping ovarian cancer screening in BRCA1/2 mutation carriers: Effects on risk management decisions & outcome of risk-reducing salpingo-oophorectomy specimens

Maturitas

Volumn 80, Issue 3, 2015, Pages 318-322

  Van Driel, Catheleine M G ^a   De Bock, Geertruida H ^a   Arts, Henriette J G ^a   Sie, Aisha S ^a   Hollema, Harry ^a   Oosterwijk, Jan C ^a   Mourits, Marian J E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Bilateral ovariectomy; Genes, BRCA1; Genes, BRCA2; Ovarian neoplasms prevention control; Risk reduction behavior; Time factors

Indexed keywords

ADULT; AGED; ARTICLE; AWARENESS; CANCER SCREENING; DNA DETERMINATION; FEMALE; GENE MUTATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; OCCULT CANCER; OUTCOME ASSESSMENT; OVARY CANCER; PATIENT DECISION MAKING; RISK MANAGEMENT; RISK REDUCTION; SALPINGOOOPHORECTOMY; TUMOR SUPPRESSOR GENE; CLINICAL PRACTICE; COHORT ANALYSIS; EARLY CANCER DIAGNOSIS; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; NETHERLANDS; OVARIAN NEOPLASMS; OVARIECTOMY; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; SALPINGECTOMY; UTILIZATION; YOUNG ADULT;

ADULT; AGED; COHORT STUDIES; EARLY DETECTION OF CANCER; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; MIDDLE AGED; NETHERLANDS; OVARIAN NEOPLASMS; OVARIECTOMY; PRACTICE PATTERNS, PHYSICIANS'; PROSPECTIVE STUDIES; RISK MANAGEMENT; SALPINGECTOMY; YOUNG ADULT;

EID: 84922966591     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2014.12.009     Document Type: Article

References (30)

1. N. Mavaddat, S. Peock, and D. Frost Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE J Natl Cancer Inst 105 2013 812 822
2. E.R. Woodward, H.V. Sleightholme, A.M. Considine, S. Williamson, J.M. McHugo, and D.G. Cruger Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective BJOG 114 2007 1500 1509
3. B.B.J. Hermsen, R.I. Olivier, and R.H.M. Verheijen No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study Br J Cancer 96 2007 1335 1342
4. N.M. Van der Velde, M.J.E. Mourits, and H.J.G. Arts Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? Int J Cancer 124 2009 919 923
5. D.G. Evans, K.N. Gaarenstroom, and D. Stirling Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers J Med Genet 46 2009 593 597
6. R.H.M. Verheijen, H. Boonstra, F.H. Menko, J. de Graaff, H.F.A. Vasen, and G.G. Kenter Aanbevelingen voor het beleid bij vrouwen met een erfelijk bepaalde hoge kans op gynaecologische kanker Ned Tijdschr Geneeskd 146 2002 2414 2418
7. S.C. Dowdy, M. Stefanek, and L.C. Hartmann Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy Am J Obstet Gynecol 191 2004 1113 1123
8. A. Gadducci, N. Biglia, S. Cosio, P. Sismondi, and A.R. Genazzani Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy Gynecol Endocrinol 26 2010 568 577
9. T.R. Rebbeck, M. Levin a, and A. Eisen Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers J Natl Cancer Inst 91 1999 1475 1479
10. T. Rebbeck, and H. Lynch Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations N Engl J Med 346 2002 1616 1622
11. T.R. Rebbeck, T. Friebel, and H.T. Lynch Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group J Clin Oncol 22 2004 1055 1062
12. T.R. Rebbeck, N.D. Kauff, and S.M. Domchek Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers J Natl Cancer Inst 101 2009 80 87
13. N. Kauff, J. Satagopan, and M. Robson Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation N Engl J Med 346 2002 1609 1615
14. I.E. Fakkert, M.J.E. Mourits, and L. Jansen Breast cancer incidence after risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers Cancer Prev Res (Phila) 5 2012 1291 1297
15. J.B. Madalinska, J. Hollenstein, and E. Bleiker Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer J Clin Oncol 23 2005 6890 6898
16. J.B. Madalinska, M. van Beurden, and E.M.a. Bleiker The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy J Clin Oncol 24 2006 3576 3582
17. J.V. Cohen, L. Chiel, and L. Boghossian Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy Fam Cancer 11 2012 69 75
18. R. Manchanda, M. Burnell, and A. Abdelraheim Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis BJOG 119 2012 527 536
19. a-B Skytte, A.-M. Gerdes, and M.K. Andersen Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing Clin Genet 77 2010 342 349
20. D.G.R. Evans, F. Lalloo, and L. Ashcroft Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent Cancer Epidemiol Biomarkers Prev 18 2009 2318 2324
21. A.R. Bradbury, C.N. Ibe, and J.J. Dignam Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers Genet Med 10 2008 161 166
22. G.H. De Bock, J.W. Hesselink, and C. Roorda Model of care for women at increased risk of breast and ovarian cancer Maturitas 71 2012 3 5
23. M.J. Mourits, and G.H. de Bock Managing hereditary ovarian cancer Maturitas 64 2009 172 176
24. K.a Metcalfe, D. Birenbaum-Carmeli, and J. Lubinski International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers Int J Cancer 122 2008 2017 2022
25. K.J. Lifford, L. Fraser, and A.N. Rosenthal Withdrawal from familial ovarian cancer screening for surgery: findings from a psychological evaluation study (PsyFOCS) Gynecol Oncol 124 2012 158 163
26. a. Fry, R. Rush, C. Busby-Earle, and A. Cull Deciding about prophylactic oophorectomy: what is important to women at increased risk of ovarian cancer? Prev Med (Baltim) 33 2001 578 585
27. V. Kram, T. Peretz, and M. Sagi Acceptance of preventive surgeries by Israeli women who had undergone BRCA testing Fam Cancer 5 2006 327 335
28. W. Reitsma, G.H. de Bock, J.C. Oosterwijk, J. Bart, H. Hollema, and M.J.E. Mourits Support of the fallopian tube hypothesis in a prospective series of risk-reducing salpingo-oophorectomy specimens Eur J Cancer 49 2013 132 141
29. K. Leeper, R. Garcia, E. Swisher, B. Goff, B. Greer, and P. Paley Pathologic findings in prophylactic oophorectomy specimens in high-risk women Gynecol Oncol 87 2002 52 56
30. A.P.M. Finch, J. Lubinski, and P. Møller Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation J Clin Oncol 32 2014 1547 1553